Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Merck & Co.'s Quarterly Earnings Preview: What You Need to Know

Rahway, New Jersey-based Merck & Co., Inc. (MRK) is an international healthcare company that offers human health pharmaceuticals across various areas, including Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, and other brands. Valued at a market cap of $304.5 billion, the company is expected to release its Q1 2026 earnings on Thursday, Apr. 30, before the market opens.

Ahead of the event, analysts expect the company’s loss per share to be $0.58 on a diluted basis, down 126.1% from $2.22 in the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in each of its last four quarters.

Fundamentals

See More
  • Market Capitalization, $K 304,549,248
  • Shares Outstanding, K 2,472,392
  • Annual Sales, $ 65,011 M
  • Annual Income, $ 18,254 M
  • EBIT $ 22,107 M
  • EBITDA $ 27,945 M
  • 60-Month Beta 0.26
  • Price/Sales 4.54
  • Price/Cash Flow 10.44
  • Price/Book 5.62

Options Overview Details

View History
  • Implied Volatility 31.20% (+1.10%)
  • Historical Volatility 24.10%
  • IV Percentile 61%
  • IV Rank 29.97%
  • IV High 53.48% on 04/10/25
  • IV Low 21.66% on 12/08/25
  • Expected Move (DTE 1) 2.17 (1.77%)
  • Put/Call Vol Ratio 1.70
  • Today's Volume 9,289
  • Volume Avg (30-Day) 49,365
  • Put/Call OI Ratio 0.72
  • Today's Open Interest 519,353
  • Open Int (30-Day) 531,615
  • Expected Range 120.60 to 124.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.58
  • Number of Estimates 7
  • High Estimate $2.00
  • Low Estimate $-1.63
  • Prior Year $2.22
  • Growth Rate Est. (year over year) -126.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
112.72 +9.08%
on 03/20/26
123.97 -0.81%
on 04/09/26
+5.85 (+5.00%)
since 03/09/26
3-Month
106.03 +15.97%
on 01/28/26
125.14 -1.74%
on 02/25/26
+12.43 (+11.25%)
since 01/09/26
52-Week
73.31 +67.73%
on 05/15/25
125.14 -1.74%
on 02/25/26
+41.05 (+50.12%)
since 04/09/25

Most Recent Stories

More News
Merck & Co.'s Quarterly Earnings Preview: What You Need to Know

Merck & Co. is expected to unveil its first-quarter results later this month, and analysts are projecting a triple-digit decline in profit.

XLV : 150.00 (+0.22%)
$SPX : 6,829.02 (+0.68%)
MRK : 123.16 (-0.02%)
TERN : 52.60 (-0.11%)
Aprea Therapeutics Showcases Emerging Clinical Data for WEE1 Inhibitor APR-1051

Aprea Therapeutics (APRE) recently showcased positive preliminary Phase 1 data for its next-generation WEE1 inhibitor, APR-1051, highlighting early tumor reduction in biomarker-defined cancer

AZN : 206.15 (+0.92%)
ZNTL : 4.03 (+46.01%)
MRK : 123.16 (-0.02%)
APRE : 0.6802 (-3.05%)
Moderna Is Most Shorted S&P 500 Stock Now. Is It a Contrarian Buy?

Moderna is the most shorted S&P 500 stock, with 17.8% short float. But its cancer pipeline, flu approval, and international contracts may surprise bears in 2026.

$SPX : 6,829.02 (+0.68%)
MRK : 123.16 (-0.02%)
MRNA : 51.33 (-1.48%)
Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Terns Pharmaceuticals,...

MRK : 123.16 (-0.02%)
TERN : 52.60 (-0.11%)
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of a pivotal Phase 2b/3 trial evaluating MK-8748 (also known as Tiespectus, EYE201), a novel investigational...

MRK : 123.16 (-0.02%)
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens

The KEYTRUDA regimen is the first and only PD-1 inhibitor-based treatment approved in the European Union for these patients Approval supported by data from the Phase 3...

MRK : 123.16 (-0.02%)
Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its first-quarter 2026 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on...

MRK : 123.16 (-0.02%)
Merck Just Made a Big Bet on a New Cancer Growth Engine

Merck's $6.7 billion Terns acquisition bolsters its oncology pipeline while reinforcing its strong margins, steadily growing dividend, and long-term growth.

MRK : 123.16 (-0.02%)
LLY : 961.90 (+0.90%)
ABBV : 213.27 (+0.79%)
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins

The Phase 3 CORALreef AddOn trial compared the efficacy and safety of enlicitide to bempedoic acid, ezetimibe or bempedoic acid with ezetimibe Enlicitide has the potential...

MRK : 123.16 (-0.02%)
Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

Merck’s WINREVAIR met primary endpoint of change in pulmonary vascular resistance (PVR), significantly improving the ability of blood to flow through the lungs to the heart ...

MRK : 123.16 (-0.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 130.92
2nd Resistance Point 127.27
1st Resistance Point 125.23
Last Price 123.16
1st Support Level 119.54
2nd Support Level 115.89
3rd Support Level 113.85

See More

52-Week High 125.14
Last Price 123.16
Fibonacci 61.8% 105.34
Fibonacci 50% 99.22
Fibonacci 38.2% 93.11
52-Week Low 73.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.